# reload+after+2024-01-21 18:45:15.113810
address1§350 Fifth Avenue
address2§72nd Floor Suite 7240
city§New York
state§NY
zip§10118
country§United States
phone§431 890 6360
website§https://www.hookipapharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
fullTimeEmployees§156
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Joern  Aldag', 'age': 64, 'title': 'CEO & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 549338, 'exercisedValue': 0, 'unexercisedValue': 281055}, {'maxAge': 1, 'name': 'Dr. Reinhard  Kandera Ph.D.', 'age': 54, 'title': 'CFO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 468305, 'exercisedValue': 0, 'unexercisedValue': 77565}, {'maxAge': 1, 'name': 'Ms. Christine D. Baker M.B.A.', 'age': 58, 'title': 'Executive Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 610520, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Rolf M. Zinkernagel M.D., Ph.D.', 'age': 79, 'title': 'Co-Founder', 'yearBorn': 1944, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andreas  Bergthaler', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Lukas  Flatz', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roman  Necina Ph.D.', 'age': 55, 'title': 'Chief Operations Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Klaus  Orlinger Ph.D.', 'age': 45, 'title': 'Chief Scientific Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew L. S. Beck', 'title': 'Executive Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Szumera', 'title': 'Executive Director of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.978
priceToSalesTrailing12Months§3.5877235
currency§USD
dateShortInterest§1702598400
forwardEps§-0.72
pegRatio§-0.06
exchange§NMS
quoteType§EQUITY
shortName§HOOKIPA Pharma Inc.
longName§HOOKIPA Pharma Inc.
firstTradeDateEpochUtc§1555594200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4fc7c674-d2aa-3bcd-a128-4deb756f8490
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§3.0
targetMeanPrice§5.08
targetMedianPrice§5.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§3.222
grossMargins§-2.96224
ebitdaMargins§0.0
trailingPegRatio§None
